Allergan Plc (AGN)

158.99
1.90 1.20
NYSE : Health Technology
Prev Close 160.93
Open 160.60
Day Low/High 158.31 / 161.15
52 Wk Low/High 114.27 / 197.00
Volume 3.12M
Avg Volume 4.80M
Exchange NYSE
Shares Outstanding 328.03M
Market Cap 52.90B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.84%)

Last Week's Portfolio Changes

We exited one stock, entered another, raised our price target on Kohl's and downgraded Nordstrom.

Weekly Roundup

Markets bathed in the afterglow of the strong jobs report for most of the week.

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

Dow Jumps Nearly 100 Points as Nasdaq, S&P 500 Slide

Dow Jumps Nearly 100 Points as Nasdaq, S&P 500 Slide

Stocks finished mixed on Thursday as concerns mount over the potential for a major rift on trade and tariffs when G-7 leaders meet later this week.

Jamie Dimon, Warren Buffett, Allergan and Google - 5 Things You Must Know

Jamie Dimon, Warren Buffett, Allergan and Google - 5 Things You Must Know

U.S. stock futures are higher on Thursday and stocks in Europe and Asia extend gains; Jamie Dimon and Warren Buffett urge companies to consider no longer providing quarterly earnings guidance.

Five Below Tops Expectations and 4 Other Stories to Watch Premarket Thursday

Five Below Tops Expectations and 4 Other Stories to Watch Premarket Thursday

As futures point higher, these are the headlines you need to get up to speed during your morning commute.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

Jim's Daily Rundown

Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.

Jim's Daily Rundown

Jim discusses our decision to exit Allergan, the AAP Bullpen, Apple's upcoming Worldwide Developers Conference and more!

Exiting Allergan

After a lot of patience and disappointment, we are closing our remaining small 'spec' position.

Weekly Roundup

Markets go through a short and volatile week.

Two Antibiotic Plays

Two Antibiotic Plays

They may not get all the attention, but antibiotic drugs are increasingly important.

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Allergan Pursues Strategic Divestitures; Specialty Retailers Shake Out -- ICYMI

Allergan Pursues Strategic Divestitures; Specialty Retailers Shake Out -- ICYMI

Here's what you need to know now for Wednesday, May 30.

Allergan Strategic Review is Disappointing

Company's plans to sell two small units are largely a cosmetic fix.

Allergan Says It's Looking to Sell Two of Its Units, But Not at Fire-Sale Prices

Allergan Says It's Looking to Sell Two of Its Units, But Not at Fire-Sale Prices

The Dublin-based drugmaker has wrapped up a strategic review of all its businesses, but says it's not pursuing a fire sale of its assets.

Weekly Roundup

China trade wars, North Korea tensions and oil volatility hit the markets this week.

Aegon Calls EUR 200 Million Of Perpetual Capital Securities

Aegon Calls EUR 200 Million Of Perpetual Capital Securities

Aegon announces that it is exercising its right to redeem the EUR 200 million 6% perpetual capital securities.

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.

Weekly Roundup

Markets consolidate after recent gains

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Annual Meeting Of Shareholders Adopts All Resolutions

Annual Meeting Of Shareholders Adopts All Resolutions

Aegon N.V.

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Here's what you need to know now for Thursday, May 17.

Allergan's Meury Talks Market Expansion in Aesthetics

Allergan's Meury Talks Market Expansion in Aesthetics

The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.

Jim's Daily Rundown

Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!

Jana Partners Takes Positions in Adobe, Apple, Anthem, AutoDesk, Others

Jana Partners Takes Positions in Adobe, Apple, Anthem, AutoDesk, Others

The insurgent manager who helped engineer the Amazon-Whole Foods combination opened a window into his latest allocations, any of which could become campaigns. Here's a wrap up of his investments as well as new developments from Mick McGuire's Marcato Capital and Dan Loeb's Third Point.

Weekly Roundup

The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.

Allergan Becomes #231 Most Shorted S&P 500 Component, Replacing Ross Stores

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Allergan Expects to Finish Strategic Review Quickly, CFO Says

Allergan Expects to Finish Strategic Review Quickly, CFO Says

The Dublin-based drugmaker will provide communications on the strategic review in 'weeks, not months,' Allergan CFO Matthew Walsh said at the Deutsche Bank healthcare conference.

TheStreet Quant Rating: C (Hold)